Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia: A case report

Leukemia Research

Volumn 33, Issue 11, 2009, Pages

  Olivieri, Attilio ^a   Attolico, Immacolata ^a   Cimminiello, Michele ^a   Discepoli, Giancarlo ^b   Cifarelli, Rosa Anna ^c  

^a SAN CARLO HOSPITAL   (Italy)

^b Ospedale Pediatrico G Salesi   (Italy)

^c Metapontum Agrobios   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD19 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; DNA; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; SYNDECAN 1; THIOTEPA; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; BLOOD TOXICITY; BONE MARROW BIOPSY; CAPILLARY ELECTROPHORESIS; CASE REPORT; CHIMERA; DEATH; DNA POLYMORPHISM; DRUG ERUPTION; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HOSPITAL DISCHARGE; HUMAN; HYPERBILIRUBINEMIA; IMMUNOPHENOTYPING; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MULTIPLE CYCLE TREATMENT; PATIENT REFERRAL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; GRAFT VS LEUKEMIA EFFECT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, PLASMA CELL; THALIDOMIDE; TREATMENT OUTCOME;

EID: 68949111607     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.04.025     Document Type: Letter

References (13)

1. Hayman S.R., and Fonseca R. Plasma cell leukaemia. Curr Treat Options Oncol 2 (2001) 205-216
2. Musto P., Rossini F., Gay F., et al. Efficacy and safety of bortezomib in patients with plasma cell leukaemia. Cancer 109 11 (2007) 2285-2290
3. Saccaro S., Fonseca R., Veillon D.M., et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem cell transplantation and review of the literature. Am J Hematol 78 (2005) 288-294
4. Petrucci M.T., Martini V., Levi A., et al. Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma 48 (2007) 180-182
5. Richardson P.G., Schlossman R.L., Weller E., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100 (2002) 3063-3067
6. Musto P., Pietrantuono G., Guariglia R., et al. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res 32 10 (2008) 1637-1638
7. Benson Jr. D.M., and Smith M.K. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukaemia. Leuk Lymphoma 48 7 (2007) 1423-1425
8. Lokhorst H.M., Schattenberg A., Cornelissen J.J., et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 18 (2000) 3031-3037
9. Davies F.E., Raje N., Hideshima T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98 1 (2001) 210-216
10. Keenan R.J., Eiras G., Burkart G.J., et al. Immunosuppressive properties of thalidomide. Transplantation 52 (1991) 908-910
11. Gaziev D., Galimberti M., Lucarelli G., and Polchi P. Chronic graft-versus-host disease: is there an alternative to the conventional treatment?. Bone Marrow Transplant 25 (2000) 689-696
12. Arora M., Wagner J.E., Davies S.M., et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 7 (2001) 265-273
13. Mohty M., Boiron J.M., Damaj G., Michallet A.S., Bay J.O., Faucher C., et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 34 (2004) 77-84